Molecular nature of methicillin-resistant Staphylococcus aureus derived from explosive nosocomial outbreaks of the 1980s in Japan  by Taneike, Ikue et al.
FEBS Letters 580 (2006) 2323–2334Molecular nature of methicillin-resistant Staphylococcus aureus
derived from explosive nosocomial outbreaks of the 1980s in Japan
Ikue Taneike, Taketo Otsuka, Soshi Dohmae, Kohei Saito, Kyoko Ozaki, Misao Takano,
Wataru Higuchi, Tomomi Takano, Tatsuo Yamamoto*
Division of Bacteriology, Department of Infectious Disease Control and International Medicine, Niigata University Graduate School of Medical
and Dental Sciences, 1-757, Asahimachi-dori, Niigata, Japan
Received 10 January 2006; revised 8 March 2006; accepted 17 March 2006
Available online 29 March 2006
Edited by Robert B. RussellAbstract Community-acquired methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) with Panton-Valentine leukocidin
(PVL) genes is increasing worldwide. Nosocomial outbreak-de-
rived (hospital-acquired) MRSA (HA-MRSA) in Japan in the
1980s was also largely PVL+. PVL+ HA-MRSA and CA-
MRSA shared the same multi-locus sequence type (ST30) and
methicillin resistance cassette (SCCmecIV), but were divergent
in oxacillin resistance, spa typing, PFGE analysis or clfA gene
analysis. PVL+ HA-MRSA, which probably originated in
PVL+ S. aureus ST30, was highly adhesive (carrying cna and
bbp genes), highly-toxic (carrying lukPV and sea genes) and
highly drug-resistant. PVL+ HA-MRSA was once replaced by
other PVL HA-MRSA (e.g., ST5), and is re-emerging as
CA-MRSA.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Since at least 1960, and especially in the 1980s, methicillin-
resistant Staphylococcus aureus (MRSA) has caused large,
life-threatening nosocomial outbreaks worldwide [1]. In the late
1990s, another type of MRSA called community-acquired
MRSA (CA-MRSA) also became a major concern worldwide
[2,3]. CA-MRSA is found among members of a particular com-
munity who do not otherwise exhibit established risk factors for
hospital-acquired MRSA (HA-MRSA) infections [1,3–5]. CA-
MRSA has recently been isolated even from hospitals [6–8].
A common feature of CA-MRSA is the presence of the Pan-
ton-Valentine leukocidin (PVL) gene [3,9]. PVL has been
shown to be associated with skin and soft tissue infections
(SSTIs) such as severe furunculosis, cellulitis, and cutaneousAbbreviations: MRSA, methicillin-resistant Staphylococcus aureus;
CA-MRSA, community-acquired MRSA; HA-MRSA, hospital-ac-
quired MRSA; PVL, Panton-Valentine leukocidin; MLST, multi-locus
sequence typing; SCCmec, staphylococcal cassette chromosome mec
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doi:10.1016/j.febslet.2006.03.049abscess, and also with sepsis and osteomyelitis [9,10]. In addi-
tion, CA-MRSA is associated with community-onset pneumo-
nia (post-inﬂuenza, necrotizing pneumonia with high
mortality) in children and young adults [11–13]. PVL induces
polymorphonuclear cell death by necrosis or by apoptosis
[14]. Thus, CA-MRSA is considered highly virulent.
CA-MRSA also carries a type IV methicillin-resistance lo-
cus, called staphylococcal cassette chromosome mecIV
(SCCmecIV), in many cases, and exhibits a low level of oxacil-
lin resistance, compared with HA-MRSA [3,9,15]. CA-MRSA
has been shown to originate from PVL+ methicillin-susceptible
S. aureus (MSSA) by acquiring SCCmec [16].
CA-MRSA is composed of multiple MRSA clones with dis-
tinct genetic backgrounds, as evidenced by (e.g.) multi-locus
sequence typing (ST) [3]. CA-MRSA has also been shown to
be continent-speciﬁc in some ST types; e.g., ST1 and ST8
mainly associated with the United States, and ST80 mainly
associated with Europe [3]. In contrast, ST30 type is seen
worldwide, including Oceania, the United States, Europe,
Japan, and Brazil [3,15,17].
MRSA from ‘‘hospital MRSA panics’’ in the 1980s in Japan
had not been examined for the presence of the PVL gene. In
this study, we demonstrate that such nosocomial outbreak-de-
rived HA-MRSA in Japan was largely PVL+. We also show
the molecular nature of PVL+ HA-MRSA, in comparison with
recent CA-MRSA and recent major HA-MRSA (PVL New
York/Japan ST5 clone).2. Materials and methods
2.1. Bacterial strains
Seventeen MRSA and 11 MSSA strains were isolated in 1985 and
1986 from blood, sputum, feces, or other specimens of hospitalized
patients in Tokyo. They were randomly chosen for antibiotic and anti-
septic resistance examinations, and were stored at 80 C. MRSA-
infected patients included those who suﬀered from pneumonia and
post-operative MRSA enteritis. Fifty-nine MRSA strains isolated from
1990 to 1992 were those from blood or cerebrospinal ﬂuid of hospital-
ized patients in Niigata; they were stored at 80 C. Three hundred
seventy-nine MRSA strains isolated from 2000 to 2005 were those
from blood, cerebrospinal ﬂuid, sputum, pleural eﬀusion, or urine of
hospitalized patients (in NICUs, ICUs and other hospital wards) in
Tokyo and Niigata. Eighteen MRSA strains were from patients with
bullous impetigo or cutaneous abscess from 2003 to 2005. CA-MRSA
ST30 strains used were NN1 (isolated from bullous impetigo in 2003)
and NN12 (isolated from abscess in 2004) from Japan [15], USA1100
from the United States (provided by L.K. McDougal and L.L.
McDonald), HT20030336 from the Netherlands and HT20010466
from Australia (provided by J. Etienne).blished by Elsevier B.V. All rights reserved.
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patients who had no history of hospitalization within the past one
year, and presented no other established risk factors for MRSA infec-
tions, such as surgery, residence in a long-term care facility, dialysis, or
indwelling percutaneous medical devices and catheters [1,3–5]. HA-
MRSA was deﬁned as MRSA isolated from hospitalized patients 48
h or later after hospitalization.
S. aureus RN2677 [18], which was resistant to rifampin (100 lg/ml)
and novobiocin (6 lg/ml), and restriction-negative, was used as a plas-
mid-free strain (recipient) in plasmid transfer experiments.
2.2. Molecular typing
Multi-locus sequence typing (MLST) was performed using seven
housekeeping genes, as previously described [19]. An allelic proﬁle (al-
lele no.) was obtained from the MLST website (http://www.mlst.net/)
and the ST data were further analyzed using eBURST-software [20]
to determine a clonal complex (CC), to which each ST belonged. spa
(staphylococcal protein A gene) typing was performed as previously
described [21]. The spa type was determined using a public spa type
data base (http://tools.egenomics.com/). Detection of the accessory
gene regulator (agr) allele group was done by PCR with the reported
primers, as previously described [22]. The SCCmec types (I–IV) were
analyzed by PCR as previously described [23], using reference strains.
In the case of SCCmecIV, three subtypes (IVa, IVb, and IVc) were fur-
ther analyzed by PCR with the reported primers, as previously
described [24].
2.3. Virulence gene analysis
Forty-one staphylococcal virulence genes were detected by PCR
using the previously reported primers. The targeted genes were 3 leu-
kocidin genes [25], 5 hemolysin genes [25], 16 staphylococcal entero-
toxin (SE) genes [25–30], 1 putative staphylococcal enterotoxin
(SEU) gene [31], 3 exfoliative toxin (ET) genes [26,32], an exotoxin-like
gene cluster [33], the epidermal cell diﬀerentiation inhibitor (EDIN)
gene [25] and 11 adhesin genes [34–36].
2.4. Drug resistance gene analysis
Resistance genes were detected by PCR. They included genes for
methicillin resistance [23], penicillin resistance [37], cadmium resistance
[38], aminoglycoside resistance [37,39,40], macrolide resistance [37] and
tetracycline resistance [41–43].
2.5. Coagulase typing
The coagulase type of MRSA and MSSA strains was examined
using a staphylococcal coagulase antiserum kit (Denka Seiken, Tokyo,
Japan) in accordance with the manufacturer’s instructions.2.6. Susceptibility testing
Susceptibility testing of bacterial strains was done by agar dilution
method with Mueller–Hinton agar according to previous procedures
[44,45]. The ﬁnal concentrations of antimicrobial agents were from
0.002 to 128 lg/ml.
2.7. Plasmid transfer and analysis
MRSA strains (donors) were mated with S. aureus RN2677 (recipi-
ent) on membrane ﬁlters, as previously described [18]. Transconjugants
were selected for both donor resistance markers (cadmium acetate at
10 lg/ml, kanamycin at 10 lg/ml, erythromycin at 10 lg/ml, or tetra-
cycline at 2 lg/ml) and recipient resistance markers (novobiocin at 5
lg/ml). Plasmid was isolated using a Qiagen Plasmid Midi kit (Qiagen,
Hilden, Germany) and lysostaphin (Wako Pure Chemicals, Osaka, Ja-
pan), according to the instructions of the manufacturer, and analyzed
by agarose gel electrophoresis. In some experiments, plasmid DNA
was introduced into S. aureusRN2677 by electroporation using a Gene
Pulser II electroporator (Bio-Rad, Tokyo, Japan), according to the
manufacturer’s instructions. Brieﬂy, RN2677 cells were grown at 37
C in brain heart infusion broth (BHI broth, Difco, Sparks, MD,
USA) to a log phase (OD600 of 0.3). Bacterial cells from 100 ml culture
were harvested, washed with 40 ml of cold sterilized water twice, sus-
pended in 10 ml of cold 10% (v/v) glycerol, and ﬁnally in 0.5 ml of cold
10% (v/v) glycerol. Competent cells (50 ll) thus made were mixed with
1 ll of plasmid DNA, and the mixture was subjected to electroporationin a 0.2 cm electrode spacing cuvette (Bio-Rad) with a setting (100 X,
2.5 kV, 25 lF). One ml of BHI broth was then added, and then incu-
bated for 90 min at 37 C. Resistance plasmid-containing clones were
selected on agar plates, as above.
2.8. Pulsed-ﬁeld gel electrophoresis (PFGE) and computer analysis
For PFGE analysis, total bacterial DNA was extracted from MRSA
or MSSA and digested with SmaI [46]. The digested DNA was applied
on PFGE (1.2% agarose). Computer-assisted analysis of the PFGE
patterns was performed using a program called Molecular Analyst
Finger Printing PLUS (Bio-Rad), according to the UPGMA clustering
algorithm [47].
2.9. Assay for mRNA expression of mecA
Bacteria were cultured in BHI broth to a log phase, and RNA was
isolated using RiboPure-Bacteria (Ambion, Austin, TX, USA).
Then, cDNA was synthesized using a reverse transcription reactions
SuperScript First-Strand Synthesis System for an RT-PCR kit
(Invitrogen, Carlsbad, CA, USA), followed by quantitative real-time
PCR assay. To amplify for the 83-bp 16S rRNA and 155-bp mecA
gene sequences, the 16S rRNA primers [48] and the primers
MECA-F1 and MECA-R1 [49] were used, respectively. A real-time
PCR assay was performed using SYBR Green I dye (Applied Biosys-
tems, Foster City, CA, USA), following the manufacturer’s direc-
tions, in triplicate. The average number of mecA copies was divided
by the average number of 16S rRNA copies to obtain each normali-
zation value.
2.10. Analysis of mecA product PBP2 0 levels
Bacteria were grown in BHI broth and the amount of PBP20 in the
1 · 108 cells were measured using an MRSA-screen kit (Denka Seiken)
in accordance with the manufacturer’s instructions. Two-fold serial
dilutions of the bacterial suspension were made and the highest dilu-
tion to obtain positive results in the assay was used as a titer for each
bacterial sample.2.11. Sequence analysis of virulence or drug resistance genes
PCR primers used for gene ampliﬁcation to determine the nucleotide
sequence included primers PVL-1 to 4 [49] for the PVL gene (lukPVSF),
5 0-ATCGTGCATTGTCGTTTG (S6F) and 5 0-CCCTAATTAACAA-
CCTACCTT (S10R) for the entire clumping factor A gene (clfA),
5 0-CTTATATTGACCCTGAAAATG (S4F) or 5 0-AAGGTGATT-
TAGCTTTACGTTC (S17F) and 5 0-CCCTAATTAACAACCTACC-
TT (S10R) or 5 0-TAGCCTCATTTTTATTTGAAGC (S17R) for
region R of clfA, 5 0-GCTTATCAGTTGATGATGCG (SCCmecF)
and 5 0-ATGAAAATCACCATTTTAGCTG (SCCmecR) for SCCme-
cIVc, 5 0-GATATGACGATTCCAATGAC (mecAF) and 5 0-TAAG-
GGAGAAGTAACAGCAC (mecAR) for mecA, and 5 0-TCCAGTT-
GAAACTCTTGC (S8F) and 5 0-CACCTATAATTAAACTATT-
CATC (S6R) for the penicillinase (PCase) gene region carrying three
genes blaI, R, Z.3. Results
3.1. Distribution of the PVL genes among MRSA in the past and
at present
For hospital isolates, a large portion of MRSA (23.5%) in
the 1980s was PVL+ (Table 1); the four PVL+ strains detected
were designated as 80s-1, 80s-2, 80s-3 and 80s-4. In addition, 1
of 11 MSSA strains was also PVL+; this PVL+ strain was des-
ignated as 80s-S. In the 1990s, only 2 out of 59 MRSA (3.4%)
were PVL+; these two PVL+ strains were designated as 90s-1
and 90s-2. No PVL+ MRSA was detected in the 2000s
(<0.3%).
For community isolates, 1 (strain NN1) of 16 MRSA strains
(6.3%) isolated from patients with bullous impetigo and one
(strain NN12) of two MRSA strains from patients with cuta-
neous abscess were PVL+ (Table 1).
Table 1
Frequency of PVL+ clones in MRSA isolated in hospitals or
community
Isolation year PVL+/total
MRSA isolated from
hospitalized patients
MRSA isolated from
the community
1985–1986a 4/17 (23.5%) –b
1990–1992 2/59 (3.4%) –b
2000–2005 0/379 (<0.3%) 1/16 (6.3%)c
1/2d
aPVL+/total in MSSA was 1/11.
bData were not available.
cMRSA was isolated from patients with bullous impetigo.
dMRSA was isolated from patients with cutaneous abscess.
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comparison with CA-MRSA
In order to investigate evolutionary relationships and the
characteristics of virulence and drug resistance, four PVL+
HA-MRSA strains (strains 80s-1 to 4) and one PVL+ MSSA
strain (strain 80s-S) isolated in the 1980s, two PVL+ HA-
MRSA strains (strains 90s-1 and 2) isolated in the 1990s and
CA-MRSA strains isolated in the 2000s were examined for
genotypes, virulence genes and drug resistance genes or PCase
plasmids (Table 2). The PVL+ HA-MRSA and PVL+ MSSA
strains all belonged to ST30, similar to CA-MRSA. They also
shared the same characteristics of agr3, coagulase type IV, and
SCCmecIV (except for PVL+ MSSA strain 80s-S, which lacked
SCCmec).
There was divergence between PVL+ HA-MRSA (or PVL+
MSSA) and CA-MRSA. The spa type of PVL+ HA-MRSA
(and PVL+ MSSA) was type43, while that of CA-MRSA
was type19 or 654 (although those spa sequence proﬁles show
a similarity to each other, as shown in Table 2). And, although
both PVL+ HA-MRSA and CA-MRSA included two subtypes
of SCCmecIV (IVa and IVc), only the PVL+ HA-MRSA group
had an unknown subtype (IVx) other than IVa, IVb or IVc.
Regarding toxin genes, PVL+ HA-MRSA and PVL+ MSSA
strains possessed hlb (for b-hemolysin) and sea (for SEA) in
many cases, in contrast to CA-MRSA. PVL+ HA-MRSA,
PVL+ MSSA and CA-MRSA strains all possessed egc (entero-
toxin gene cluster) consisting of ﬁve genes (seg, sei, sem, sen
and seo) plus seu, except for strain 80s-2 (which lacked sen).
Regarding adhesin genes, PVL+ HA-MRSA, PVL+ MSSA
and CA-MRSA strains all possessed 10 of the 11 genes exam-
ined (except for CA-MRSA strains NN1 and NN12, which
lacked icaA [for bioﬁlm formation]); all the strains lacked fnbB
(for ﬁbronectin-binding protein B).
As for drug resistance, the PVL+ HA-MRSA strains of the
1980s all manifested high levels of oxacillin resistance (MIC,
P 128 lg/ml), in contrast to CA-MRSA (MIC, 32 lg/ml)
(although the oxacillin resistance levels of PVL+ HA-MRSA
of the 1990s were low). A penicillin- and cadmium-resistant
plasmid (PCase plasmid) was present in all the PVL+ HA-
MRSA and CA-MRSA strains, except for PVL+ HA-MRSA
strain 80s-2. Such self-transmissible PCase plasmids of PVL+
HA-MRSA, but not of CA-MRSA, conferred to its hosts
(strain RN2677) additional multiple drug resistance (kanamy-
cin and streptomycin resistance, and erythromycin/clindamy-
cin resistance in some cases). Some tetracycline, gentamicin
or kanamycin resistance was also separately transferred to
RN2677.Thus, a comparison of PVL+ HA-MRSA and present CA-
MRSA (Table 2) showed that although the two PVL+ MRSA
clones shared many common characteristics (such as ST30,
agr3, SCCmecIV, coagulase type IV and the presence of PVL
genes), there was divergence between them; only PVL+ HA-
MRSA exibited the spa43 type and SCCmecIVx (unknown)
subtype, and had hemolysin gene hlb, enterotoxin (superanti-
gen) gene sea and a multiple drug-resistant PCase plasmid.
There were no virulence genes, which were present in CA-
MRSA, but not in PVL+ HA-MRSA. Analysis of PVL+
MSSA (Table 2) demonstrated that it closely resembled
PVL+ HA-MRSA with only some diﬀerences, indicating that
PVL+ HA-MRSA evolved from PVL+ MSSA.
3.3. Comparison with a major HA-MRSA clone in the 2000s
Next, to gain an understanding of the virulence or drug
resistance characteristics of PVL+ HA-MRSA of the 1980s
and 1990s, comparison was also made with a major HA-
MRSA clone (New York/Japan clone: ST5, SCCmecII, PVL)
in Japan, isolated in the 2000s (Table 2).
PVL+ HA-MRSA of the 1980s and 1990s and HA-MRSA of
the 2000s shared similar characteristics such as the presence of
toxin genes (hlb and sea) and a high oxacillin resistance level
(MIC, P 128 lg/ml) (Table 2). In addition, tetM (for minocy-
cline [and teteracycline] resistance) was found only in these
MRSA groups.
However, there was divergence; e.g., PVL+ HA-MRSA
lacked toxin genes tst (for toxic shock syndrome toxin 1) and
sec (for SEC), and possessed enterotoxin gene seu in egc and
adhesin genes cna (for collagen-binding protein) and bbp (for
bone sialoprotein-binding protein), in contrast to HA-MRSA
of the 2000s. Unexpectedly, no multiple drug-resistant PCase
plasmid was found in HA-MRSA of the 2000s.
Thus, PVL+ HA-MRSA was as virulent as present HA-
MRSA in terms of the presence of hlb and sea (or tetM)
(although they lacked tst and sec), and more adhesive in terms
of the presence of cna and bbp (similar to CA-MRSA).3.4. Cluster analysis of PFGE patterns
A computer-assisted comparison of PFGE patterns obtained
with PVL+ HA-MRSA, PVL+ MSSA and CA-MRSA strains
is shown in Fig. 1. Consistent with the spa typing, PVL+
HA-MRSA and PVL+ MSSA strains (spa43) constituted
sub-clusters, which were distinguished from a sub-cluster of
CA-MRSA (spa19 or 654) strains.
3.5. Divergence in the clfA gene sequences
The entire sequences or region R ([Asp-Ser]-repeating re-
gion) sequences of the clfA gene of PVL+ HA-MRSA, PVL+
MSSA and CA-MRSA were determined, and compared with
the reported clfA sequence of S. aureus Newman or to each
other (Fig. 2). The entire sequences of the clfA gene of PVL+
HA-MRSA strain 80s-2 and CA-MRSA strain NN1 showed
100% similarity in the regions of S (signal peptide region), A
(region including a ligand-binding domain), W (wall-anchor-
ing, spanning region), M (membrane-spanning region) and C
(cytoplasmic tail region consisting of positively charged amino
acid residues) (Fig. 2A). However, in region R, there were
insertions (or deletions) showing a marked divergence.
Region R sequence analysis clearly distinguished three
groups: a PVL+ HA-MRSA/PVL+ MSSA group, a
Table 2
Characteristics of PVL+ MSSA and PVL+ HA-MRSA in the past and CA-MRSA and HA-MRSA at present
Type,
gene, or
resistance
PVL+
MSSA
isolated
in the
1980s
PVL+ HA-MRSA isolated in: CA-MRSA
isolated in the
2000s
CA-MRSA isolated from foreign
countries
HA-MRSA isolated in
the 2000s
the 1980s the 1990s
80s-S 80s-1 80s-2 80s-3 80s-4 90s-1 90s-2 NN1 NN12 USA
1100
(USA)
HT2003
0336
(Netherlands)
HT2001
0466
(Australia)
E6 (from
NTED)a
I6 (from
TSS)b
Types
CCc 30 30 30 30 30 30 30 30 30 30 30 30 5 5
STd 30 30 30 30 30 30 30 30 30 30 30 30 5 5
spa 43 43 43 43 43 43 43 19 19 19 654 19 2 24
(WGKAK
AOMQ)
(WGKAK
AOMQ)
(WGKAK
AOMQ)
(WGKAK
AOMQ)
(WGKAK
AOMQ)
(WGKAK
AOMQ)
(WGKAK
AOMQ)
(XKAK
AOMQ)
(XKAK
AOMQ)
(XKAK
AOMQ)
(XKB
AOMQ)
(XKAK
AOMQ)
(TJMBM
DMGMK)
(TJMEM
DMGMK)
agr 3 3 3 3 3 3 3 3 3 3 3 3 2 2
SCCmec
type
 IVxe IVc IVa IVa IVxe IVc IVc IVc IVa IVc IVa IIa IIa
Coagulase
type
IV IV IV IV IV IV IV IV IV IV IV IV II II
Virulence genes
Leukocidins
lukPVSF +
f +f +f +f +f + + +f + +f +f +f  
lukE-lukD + + + + + + + + + + + + + +
lukM              
Hemolysins
hla + + + + + + + + + + + + + +
hlb +  + + +  +      + +
hlg + + + + + + + + +  + + + +
hlg-v              +
hld + + + + + + + + + + + + + +
Staphylococcal enterotoxins
tst             + +
sea  + +  + + +       +
seb              
sec             + +
sed              
see              
seg + + + + + + + + + + + + + +
seh              
sei + + + + + + + + + + + + + +
sej              
sek              
sem + + + + + + + + + + + + + +
sen + +  + + + + + + + + + + +
seo + + + + + + + + + + + + + +
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resistance in the
1980s
the 1980s the 1990s
80s-S 80s-1 80s-2 80s-3 80s-4 90s-1 90s-2 NN1 NN12 USA
1100
(USA)
HT2003
0336
(Netherlands)
HT2001
0466
(Australia)
E6 (from
NTED)a
I6 (from
TSS)b
sep              
seq              
seu + + + + + + + + + + + +  
Exfoliative toxins
eta              
etb              
etd              
Other toxins
set + + + + + + + + + + + + + +
edin              
Adhesions
clfA + + + + + + + + + + + + + +
clfB + + + + + + + + + + + + + +
fnbA + + + + + + + + + + + + + +
fnbB              
cna + + + + + + + + + + + +  
eno + + + + + + + + + + + + + +
icaA + + + + + + +   + + + + +
icaD + + + + + + + + + + + + + +
ebpS + + + + + + + + + + + + + +
ﬁb + + + + + + + + + + + + + +
bbp + + + + + + + + + + + +  
Drug resistanceg and genes
mecA
(MIC of
OXA, lg/ml)
 (0.25) + (P 256) + (128) + (P 256) + (128) + (32) + (32) + (32) + (32) + (32) + (32) + (32) + (P 256) + (P 256)
PCase
plasmid
 + h  + h + h + h + h + h + h + h + h + h + h 
Carried genes (resistance)
blaZ (PC)  +  + + + + + + + + + + 
aph(30)-IIIa
(KM)
 +  + + + +       
aadE (SM)  +  + + + +       
ermB (EM, CLDM)    + + +        
cadD,X (Cd)   i   i  i  i  i + + +  i + + 
Other transferred genes (resistance)
tetK (TC) + j   + j + j  + j  + k     
aac(60)-aph(200)
(GM, KM)
        + k     + l
Other genes (resistance)m
aph(30)-IIIa
(KM)
     +        
ant(4 0)-I (KM)    +          +
aac(60)-aph(200)
(GM, KM)
 + + + + +        
aadE (SM)              
ermA
(EM, CLDM)
+ +(i) n +(i) n + +  (+)o      + +
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Table 2 (continued)
Type,
gene,
or
resistance
PVL+
MSSA
isolated
in the
1980s
PVL+ HA-MRSA isolated in: CA-MRSA
isolated in the
2000s
CA-MRSA isolated from foreign
countries
HA-MRSA isolated in
the 2000s
the 1980s the 1990s
80s-S 80s-1 80s-2 80s-3 80s-4 90s-1 90s-2 NN1 NN12 USA
1100
(USA)
HT2003
0336
(Netherlands)
HT2001
0466
(Australia)
E6 (from
NTED)a
I6 (from
TSS)b
ermB
(EM, CLDM)
+             
tetM
(TC, MINO)
 +           + +
aNTED, neonatal toxic shock syndrome-like exanthematous disease. NTED is caused by MRSA infection in neonates in a neonatal intensive care unit (NICU). It frequently occurs at 2–4 days old and
the major symptoms are fever and subsequent exanthema. The fever persists for about one day and decreases spontaneously. The exanthema is systemic erythema (2–3 mm erythemas later fuse)
spreading over the face, trunk, all four limbs, palms, and soles, spontaneously diminishing within 2–3 days. A superantigen TSST-1 (encoded by tst) is the major cause of NTED [50]. Strain E6 was
isolated from the umbilical blennorrhoea of an infant (female aged 5 days old) with NTED in Niigata [51].
bTSS, toxic shock syndrome. TSS is a life-threatening staphylococcal infection usually for adults [52]. Although most of HA-MRSA in hospitals in Japan possess tst, the development of TSS is rare in
hospitals (the reason for this is not known). However, when TSS develops, it is very severe, and may lead to death. TSST-1 is the major causative toxin of TSS. Strain I6 was isolated from a patient
(male aged 59 years old) with TSS in Niigata [15].
cCC, clonal complex.
dST, multi-locus sequence type.
eType IV with unknown subtypes (other than IVa, IVb or IVc).
fPVL gene sequences were identical to the NN1 sequence (AB186917); GenBank Accession Nos. for strains 80s-S, 80s-1 to 4, USA1100, HT20030336 and HT20010466 were AB245448, AB245449,
AB245450, AB245451, AB245452, AB245453, AB245454 and AB245455, respectively.
gResistance: OXA, oxacillin; PC, penicillin G (or ampicillin); KM, kanamycin; SM, streptomycin; EM, erythromycin; CLDM, clindamycin; TC, tetracycline; GM, gentamicin; MINO, minocycline; Cd,
cadmium.
hPCase (penicillin- and Cd- resistant) plasmid (size in kb) for strains 80s-1, 80s-3, 80s-4, 90s-1, 90s-2, NN1, NN12, USA1100, HT20030336, HT20010466 and strain E6 were pAC80s1 (37 kb), pAC80s3
(42 kb), pAC80s4 (44 kb), pAC90s1 (46 kb), pAC90s2 (29 kb), pAC00s1 (32 kb), pAC00s2 (32 kb), pAC00s3 (29 kb), pAC00s4 (29 kb), pAC00s5 (29 kb) and pAC00s6 (25 kb), respectively. Of those,
pAC80s1, pAC80s3, pAC80s4, pAC00s1, pAC00s2, pAC00s3 and pAC00s5 were identiﬁed by ﬁlter mating (conjugal transfer) to S. aureus RN2677 (transfer frequency was 2.0 · 109 or lower), and
pAC90s1, pAC90s2, pAC00s4, and pAC00s6 were transferred to RN2677 by electroporation (of plasmid DNA).
iCd-resistance gene was negative for cadD,X.
jTC resistance was transferred to RN2677 by ﬁlter mating (for strains 80s-S, 80s-3 and 80s-4) or by electroporation (for strain 90s-2). TC resistance plasmids were detected for strains 80s-S, 80s-3, 80s-4
and 90s-2 (size 4.6, 4.1, 4.1 and 4.6 kb, respectively).
kStrain NN12 carried the transmissible pGKT1 plasmid (size 41 kb) carrying tetK and aac(6 0)-aph(200).
lStrain E6 carried the aac(6 0)-aph(200) gene, which could be transferred to RN2677 by electropolation.
mDrug resistance was not transferred to RN2677 by conjugation or electroporation.
nInducible clindamycin resistance.
oClindamycin intermediate resistance.
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Fig. 1. PFGE analysis of PVL+ HA-MRSA, PVL+ MSSA and CA-MRSA, and dendrogram constructed by computer-assisted comparison. PFGE
patterns (right side) were obtained after DNA digestion with SmaI. Strain numbers are shown at the right side of the dendrogram (or at the left side
of the PFGE patterns). In the dendrogram, sub-clusters consisting of spa43 strains and those consisting of spa19 and 654 strains are separately
marked with shading.
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The CA-MRSA group had segment S-3, the PVL+ HA-
MRSA/PVL+ MSSA group had segments S-1 and S-2 and
the foreign CA-MRSA group had segments S-1 and S-3.
In addition, strain 90s-2 showed a strain-speciﬁc deletion of
segment S-4 (Fig. 2A, *1). Strains 80s-1 and 90s-1 exhibited a
non-synonymous substitution Gﬁ T (Aspﬁ Tyr) (Fig. 2A,
*2), and strains USA1100 and HT20010466 exhibited a synon-
ymous substitution Aﬁ C (Fig. 2A, *3).
The sequences of the divergent segments (S-1 to 4) are shown
in Fig. 2B. S-1 was a four-times repetition of the (Asp-Ser)3
unit (18 bp), with substitution (Aspﬁ Gly, Asn or Thr) at
six positions (Fig. 2B). S-2 to S-4 were a twice repetition of
the (Asp-Ser)3 unit (18 bp), with one substitution (Aspﬁ Glu)
in S-4.
3.6. Divergence in the SCCmecIV sequences
Since PVL+ HA-MRSA of the 1980s showed a higher level
of oxacillin resistance than did present CA-MRSA (Table 2),
the entire sequences of SCCmecIVc of PVL+ HA-MRSA strain
80s-2 (MIC of oxacillin, 128 lg/ml) and CA-MRSA strain
NN1 (MIC of oxacillin, 32 lg/ml) were determined, and com-
pared with each other (Fig. 3). The SCCmecIVc sequence at
the 3 0 end (including mecA and ccrB genes) was well conserved
with only four nucleotides changed, while the sequence at the
5 0 end (including the ccrA gene) was slightly divergent.
Consistent with high oxacillin MIC levels, PVL+ HA-MRSA
strains (80s-1 to 4) manifested higher mecA transcription and
PBP2 0 production, compared with CA-MRSA strains (NN1
and NN12) (Table 3). PVL+ HA-MRSA strains possessed
Shine-Dalgarno (SD) sequence with Gﬁ T substitution (with
a lower DG value) that may aﬀect translation eﬃciency (Fig. 3
and Table 3). There was animo acid substitution in the mecA
product (PBP2 0) at position 146 or 246 (Table 3), but not con-
tributing to the diﬀerent level of oxacillin resistance (Asn and
Gly at positions 146 and 246 were seen in both PVL+ HA-
MRSA and CA-MRSA).
Since the regulatory genes blaI (for repressor) and blaR (for
a sensor-transducer) on a PCase plasmid, which regulate theexpression of blaZ (for PCase), may also aﬀect expression of
the mecA gene on SCCmec, the gene sequences of blaI and
blaR (and blaZ for PCase) on PCase plasmids of strains 80s-
3 and NN1 were determined. They were identical to each other
(or showed only substitution between homologous amino
acids) (Table 3), indicating no regulatory eﬀects on the oxacil-
lin resistance of these blaI and blaR genes.4. Discussion
In this study, the authors demonstrated that MRSA from
hospitalized patients in the 1980s (when ‘‘hospital MRSA pan-
ics’’ occurred in Japan) was largely PVL+. To our knowledge,
this study provides the ﬁrst molecular characterization of such
PVL+ HA-MRSA. Since CA-MRSA, described in the United
States and Europe, is considered to be a highly virulent MRSA
[3,11,12], and the PVL gene of PVL+ HA-MRSA was identical
to those of CA-MRSA, PVL+ HA-MRSA could also have
been virulent.
Regarding diseases, for instance, decubitus, pneumonia, bac-
teremia and post-operative MRSA enteritis in elder (or adult)
patients [54–56] and bacteremia and abscess in pediatric pa-
tients [57] were frequently found in the late 1980s and the early
1990s, but have drastically decreased recently. Of PVL+ HA-
MRSA examined, one strain (80s-4) from the 1980s was associ-
ated with pneumonia (no records were available for three
remaining strains), and two strains from the 1990s were derived
from blood. PVL+ HA-MRSA might not be associated with
MRSA enteritis, because two HA-MRSA strains isolated in
the 1980s from MRSA enteritis (and examined in this study)
were PVL; the strains were positive for at least tst, sea and sec.
PVL+ HA-MRSA belonged to ST30, just like CA-MRSA,
but the two MRSAs were unambiguously divergent, as evi-
denced by spa typing, PFGE analysis, mecA SD sequence anal-
ysis, sequence analysis of the clfA R region, or oxacillin MIC
analysis. The former has been replaced by the latter. PVL+
HA-MRSA seems to have originated in PVL+ MSSA ST30
in the 1980s or before. A possible ancestor (PVL+ MSSA
NN1, NN12
80s-S, 80s-1-4,
90s-1, 2
USA1100,
HT20030336,
HT20010466
NN1, NN12
80s-S, 80s-1-4,
90s-1, 2
USA1100,
HT20030336,
HT20010466
NN1, NN12
80s-S, 80s-1-4,
90s-1
90s-2
USA1100
HT20030336
HT20010466
868 924
[bp]
[aa]40
118 1675
Ligand-binding domain
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905 933
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1707 1815
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100%
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B
Fig. 2. Sequences of the clfA gene of PVL+ HA-MRSA, PVL+ MSSA and CA-MRSA. The GenBank Accession Nos. for the entire clfA gene
sequence of strains NN1 and 80s-2 are AB245456 and AB245457, respectively. In case of strains NN12, 80s-S, 80s-1, 80s-3, 80s-4, 90s-1, 90s-2,
USA1100, HT20030336 and HT20010466, only region R sequences were determined (GenBank Accession Nos. AB245467, AB245458, AB245459,
AB245460, AB245461, AB245462, AB245463, AB245464, AB245465 and AB245466, respectively) and drawn in the ﬁgure. In A, the locations of the
regions S, A, R, W, M and C in the clfA gene are drawn based on the Newman strain data [53]. *1, deletion of 36 bp (corresponding to twice
repetition of the 6 amino acids unit) in strain 90s-2; *2, non-synonymous substitution (GACﬁ TAC, Aspﬁ Tyr; at nucleotide position 2590 of
corresponding 80s-2 sequence) in strains 80s-1 and 90s-1; *3, synonymous substitution (TCAﬁ TCC) in strains USA1100 and HT20010466. In B,
nucleotide sequences of the divergent segments (S-1 to 4) are presented. The corresponding amino acid residues are drawn below the nucleotide
sequence (amino acids that diﬀered from Asp-Ser are underlined).
2330 I. Taneike et al. / FEBS Letters 580 (2006) 2323–2334ST30) of recent CA-MRSA has not been identiﬁed yet; ST
types of recent PVL+ MSSA in Japan (so far examined) are
ST50 and ST508.
In hospitals in Japan, it seems that PVL+ HA-MRSA ST30
was a dominant clone in the early 1980s. Then, this clone was
replaced by an other PVL HA-MRSA clone (New York/Ja-pan ST5) in the 1990s. The present dominant HA-MRSA
clone is still New York/Japan ST5. This replacement seems
to have occurred in many hospitals in Japan, since our previ-
ous data (and reports [58]) showed that coagulase type IV
MRSA was dominant in the early 1980s and then replaced
by coagulase type II MRSA. Consistent with this, in this study,
Table 3
Oxacillin-resistance-related characteristics of PVL+ HA-MRSA and CA-MRSA
Strain MIC of
oxacillin
(lg/ml)
Relative mecA
transcript levels
(mecA/16s rRNA)
PBP2 0 production
(titer)
SD sequence
for mecA
Sequence of PBP20 a PCase plasmid genes
146 246 blaI blaR blaZ
MSSA
80s-S 0.25 0.0 <1      
PVL+ HA-MRSA
80s-1 P 256 5.2 ± 1.2 4 AAGGAGG Lys Glu + + +
(16.0 kcal) (AAA) (GAA)
80s-2 128 10.2 ± 3.8 4 AAGGAGG Asn Glu   
(16.0 kcal) (AAT) (GAA)
80s-3 P 256 13.1 ± 1.2 4 AAGGAGG Asn Gly +b +b,c +b
(16.0 kcal) (AAT) (GGA)
80s-4 128 4.4 ± 0.7 8 AAGGAGG Asn Gly + + +
(16.0 kcal) (AAT) (GGA)
CA-MRSA
NN1 32 0.8 ± 0.6 2 AAGGAGT Asn Gly +b +b,c +b
(12.0 kcal) (AAT) (GGA)
NN12 32 0.1 ± 0.02 2 NDd NDd NDd + + +
aGenBank Accession Nos. for the mecA gene sequence of strains 80s-1 to 4 and NN1 are AB221119, AB221120, AB221121, AB221122 and
AB221124, respectively.
bGenBank Accession Nos. for the blaI, blaR and blaZ gene sequences of strains 80s-3 and NN1 are AB245469 and AB245468, respectively.
cThere was a non-synonymous substitution at nucleotide position 271 (GCA, Ala in strain 80s-3; ACA, Thr in strain NN1).
dND, not determined.
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Fig. 3. SCCmecIVc sequences of PVL+ HA-MRSA (strain 80s-2) and CA-MRSA (strain NN1). The GenBank Accession Nos. for the entire
SCCmecIVc sequence of strains NN1 and 80s-2 are AB245470 and AB245471, respectively. Arrows indicate a single base substitution. Conserved
regions in the SCCmecIVc are marked with shading.
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that of New York/Japan MRSA ST5 was type II.
Also recently, the PVL+ HA-MRSA ST30 which left the
hospitals may be re-emerging as a CA-MRSA ST30 in the
community, probably losing some virulence genes such as
hlb, sea and icaA and drug resistance genes on a PCase plasmid
to become CA-MRSA. These genes found with PVL+ HA-
MRSA may be associated with hospital infection.
The reason for this dynamic MRSA replacement in Japan is
not known. However, there is a possibility that PVL+ HA-MRSA infection caused a marked increase of antibodies
against (e.g.) PVL and bacterial surface adhesins (such as those
for collagen-binding or bone sialoprotein-binding; genes cna
and bbp) in individuals, which in turn suppressed PVL+ HA-
MRSA infection and allowed emergence of PVL, cna and
bbp New York/Japan clone in hospitals, and that CA-MRSA
(PVL+, cna+ and bbp+), evolved from PVL+ HA-MRSA, is
now appearing in the community (especially in children and
adolescents) where PVL+, cna+ and bbp+ MRSA infection was
rare. Further study is necessary to examine this hypothesis.
2332 I. Taneike et al. / FEBS Letters 580 (2006) 2323–2334In this study, we also investigated clfA gene sequences to
look at divergence between PVL+ HA-MRSA and CA-MRSA.
The R domain of clumping factor A (ClfA) consists of Asp-Ser
repeats, and appears to serve as a ‘‘stalk’’ allowing presenta-
tion of the ligand-binding domain (A) at the bacterial surface
for ligand interactions [53]. In region R, thrice repetition of
Ser-Asp (18 bp long) consisted of a further repeating unit
[53]. Insertions (or deletions) observed in this study were
mainly twice or four times repetition of such an 18-bp unit,
indicating a possibility that the 36-bp long unit ([Asp-Ser]6
unit) plays a role in insertion (or deletion) recognition, and
that (Asp-Ser)6 is a basic unit in the functional ‘‘stalk’’ struc-
ture.
Interestingly, this analysis also distinguished CA-MRSA
ST30 in Japan from CA-MRSA ST30 from other countries.
Thus, sequencing of region R of clfA could be useful for bac-
terial typing.
PVL+ S. aureus adheres to collagens and laminin [13]. In this
study, we demonstrated that PVL+ HA-MRSA and CA-
MRSA carried both cna and bbp, while recent HA-MRSA
(New York/Japan clone) did not. Collagen-binding protein
(CBP) plays a role in adherence to exposed type I and IV col-
lagens after epithelial damage due to viral infection (e.g., inﬂu-
enza) [11–13]. Further, bone sialoprotein-binding protein
(BSBP) plays a role in adherence to the cells or hydroxyapatite
of bone tissue [59,60]. BSBP+ staphylococci are associated with
hematogenously spread osteomyelitis and arthritis, especially
in young persons [59]. Indeed, CA-MRSA strain NN12 was
isolated from an 18-year-old female high school student (a bas-
ketball player) with an abscess and bacteremia and subse-
quently with osteomyelitis. We concluded that the CA-
MRSA ST30 clone (and therefore PVL+ HA-MRSA) is highly
virulent in terms of tissue adherence.
In addition, PVL+ HA-MRSA (but not CA-MRSA) pos-
sessed hlb and sea. sea and lukE-lukD are associated with
post-antibiotic diarrhea [61], and sea is associated with severity
of infection (sepsis and shock) [62]. Thus, PVL+ HA-MRSA is
a genotypically highly-adhesive (CBP+, BSBP+) and highly-
toxic/superantigenic (PVL+, SEA+) clone.
PVL+ HA-MRSA in the 1980s exhibited a high level of oxa-
cillin resistance and carried a multiple drug-resistant PCase
plasmid. Minocycline resistance (tetM) was also found in this
group. These results also suggest a strong association of
PVL+ HA-MRSA with nosocomial infection. The reason
why PVL+ HA-MRSA in the 1980s (or recent HA-MRSA)
exhibited a high level of oxacillin resistance is not known.
However, there is a possibility that the divergent 5 0 side region
of SCCmec regulates the mecA transcription.
In conclusion, HA-MRSA in the 1980s (when ‘‘hospital
MRSA panics’’ occurred in Japan) was largely PVL+.
PVL+ HA-MRSA and CA-MRSA shared the same clonal
characteristics such as ST30 or SCCmecIV, but the two were
apparently divergent in spa typing, PFGE analysis, clfA
region R sequence analysis, oxacillin resistance levels, PCase
plasmid analysis and others. PVL+ HA-MRSA was highly
adhesive (possessing CBP and BSBP), highly toxic/superanti-
genic (being positive for PVL, SEA and b-hemolysin) and
highly drug-resistant (exhibiting a high level of oxacillin-
resistance and possessing a multiple drug-resistant PCase
plasmid). This genotype is unique to PVL+ HA-MRSA,
and not found in recent CA-MRSA or HA-MRSA. PVL+
HA-MRSA was replaced by the PVL New York/JapanHA-MRSA ST5 clone in the 1990s, and now is re-emerging
as CA-MRSA in the community losing some virulence
genes.
Acknowledgments: We thank Jerome Etienne for encouragement and
for supplying ST30 CA-MRSA strains, and L.K. McDougal and
L.L. McDonald for supplying ST30 CA-MRSA. This study was
supported by a Grant-in-Aid for Scientiﬁc Research from the
Ministry of Education, Culture, Sports, Science and Technology,
Japan.References
[1] Brumﬁtt, W. and Hamilton-Miller, J. (1989) Methicillin-resistant
Staphylococcus aureus. N. Engl. J. Med. 320, 1188–1196.
[2] Centers for Disease Control and Prevention. (1999) Four pedi-
atric deaths from community-acquired meticillin-resistant Staph-
ylococcus aureus – Minnesota and North Dakota, 1997–1999.
MMWR Morb. Mortal. Wkly. Rep. 48, 707–710.
[3] Vandenesch, F., Naimi, T., Enright, M.C., Lina, G., Nimmo,
G.R., Heﬀernan, H., Liassine, N., Bes, M., Greenland, T.,
Reverdy, M.E. and Etienne, J. (2003) Community-acquired
methicillin-resistant Staphylococcus aureus carrying Panton-Val-
entine leukocidin genes: worldwide emergence. Emerg. Infect. Dis.
9, 978–984.
[4] Tacconelli, E., Tumbarello, M. and Cauda, R. (1998) Staphylo-
coccus aureus infections. N. Engl. J. Med. 339, 2026–2027.
[5] Naimi, T.S., LeDell, K.H., Como-Sabetti, K., Borchardt, S.M.,
Boxrud, D.J., Etienne, J., Johnson, S.K., Vandenesch, F.,
Fridkin, S., O’Boyle, C., Danila, R.N. and Lynﬁeld, R. (2003)
Comparison of community- and health care-associated methicil-
lin-resistant Staphylococcus aureus infection. JAMA 290, 2976–
2984.
[6] Andersen, B.M., Bergh, K., Steinbakk, M., Syversen, G., Magn-
aes, B., Dalen, H. and Bruun, J.N. (1999) A Norwegian
nosocomial outbreak of methicillin-resistant Staphylococcus
aureus resistant to fusidic acid and susceptible to other antistaph-
ylococcal agents. J. Hosp. Infect. 41, 123–132.
[7] Saiman, L., O’Keefe, M., Graham 3rd, P.L., Wu, F., Said-Salim,
B., Kreiswirth, B., LaSala, A., Schlievert, P.M. and Della-Latta,
P. (2003) Hospital transmission of community-acquired methicil-
lin-resistant Staphylococcus aureus among postpartum women.
Clin. Infect. Dis. 37, 1313–1319.
[8] O’Brien, F.G., Lim, T.T., Chong, F.N., Coombs, G.W., Enright,
M.C., Robinson, D.A., Monk, A., Said-Salim, B., Kreiswirth,
B.N. and Grubb, W.B. (2004) Diversity among community
isolates of methicillin-resistant Staphylococcus aureus in Australia.
J. Clin. Microbiol. 42, 3185–3190.
[9] Zetola, N., Francis, J.S., Nuermberger, E.L. and Bishai, W.R.
(2005) Community-acquired meticillin-resistant Staphylococcus
aureus: an emerging threat. Lancet Infect. Dis. 5, 275–286.
[10] Lina, G., Pie´mont, Y., Godail-Gamot, F., Bes, M., Peter, M.O.,
Gauduchon, V., Vandenesch, F. and Etienne, J. (1999) Involve-
ment of Panton-Valentine leukocidin-producing Staphylococcus
aureus in primary skin infections and pneumonia. Clin. Infect.
Dis. 29, 1128–1132.
[11] Francis, J.S., Doherty, M.C., Lopatin, U., Johnston, C.P., Sinha,
G., Ross, T., Cai, M., Hansel, N.N., Perl, T., Ticehurst, J.R.,
Carroll, K., Thomas, D.L., Nuermberger, E. and Bartlett, J.G.
(2005) Severe community-onset pneumonia in healthy adults
caused by methicillin-resistant Staphylococcus aureus carrying the
Panton-Valentine leukocidin genes. Clin. Infect. Dis. 40, 100–107.
[12] Gillet, Y., Issartel, B., Vanhems, P., Fournet, J.C., Lina, G., Bes,
M., Vandenesch, F., Pie´mont, Y., Brousse, N., Floret, D. and
Etienne, J. (2002) Association between Staphylococcus aureus
strains carrying gene for Panton-Valentine leukocidin and highly
lethal necrotising pneumonia in young immunocompetent pa-
tients. Lancet. 359, 753–759.
[13] de Bentzmann, S., Tristan, A., Etienne, J., Brousse, N., Vande-
nesch, F. and Lina, G. (2004) Staphylococcus aureus isolates
associated with necrotizing pneumonia bind to basement mem-
brane type I and IV collagens and laminin. J. Infect. Dis. 190,
1506–1515.
I. Taneike et al. / FEBS Letters 580 (2006) 2323–2334 2333[14] Genestier, A.L., Michallet, M.C., Pre´vost, G., Bellot, G., Chal-
abreysse, L., Peyrol, S., Thivolet, F., Etienne, J., Lina, G.,
Vallette, F.M., Vandenesch, F. and Genestier, L. (2005) Staph-
ylococcus aureus Panton-Valentine leukocidin directly targets
mitochondria and induces Bax-independent apoptosis of human
neutrophils. J. Clin. Invest. 115, 3117–3127.
[15] Takizawa, Y., Taneike, I., Nakagawa, S., Oishi, T., Nitahara, Y.,
Iwakura, N., Ozaki, K., Takano, M., Nakayama, T. and
Yamamoto, T. (2005) A Panton-Valentine leucocidin (PVL)-
positive community-acquired methicillin-resistant Staphylococcus
aureus (MRSA) strain, another such strain carrying a multiple-
drug resistance plasmid, and other more-typical PVL-negative
MRSA strains found in Japan. J. Clin. Microbiol. 43, 3356–3363.
[16] Mongkolrattanothai, K., Boyle, S., Kahana, M.D. and Daum,
R.S. (2003) Severe Staphylococcus aureus infections caused by
clonally related community-acquired methicillin-susceptible and
methicillin-resistant isolates. Clin. Infect. Dis. 37, 1050–1058.
[17] Ribeiro, A., Dias, C., Silva-Carvalho, M.C., Berquo´, L., Ferreira,
F.A., Santos, R.N.S., Ferreira-Carvalho, B.T. and Figueiredo,
A.M. (2005) First report of infection with community-acquired
methicillin-resistant Staphylococcus aureus in South America. J.
Clin. Microbiol. 43, 1985–1988.
[18] Yamamoto, T., Tamura, Y. and Yokota, T. (1988) Antiseptic and
antibiotic resistance plasmid in Staphylococcus aureus that pos-
sesses ability to confer chlorhexidine and acrinol resistance.
Antimicrob. Agents Chemother. 32, 932–935.
[19] Enright, M.C., Day, N.P., Davies, C.E., Peacock, S.J. and Spratt,
B.G. (2000) Multilocus sequence typing for characterization of
methicillin-resistant and methicillin-susceptible clones of Staphy-
lococcus aureus. J. Clin. Microbiol. 38, 1008–1015.
[20] Feil, E.J., Li, B.C., Aanensen, D.M., Hanage, W.P. and Spratt,
B.G. (2004) eBURST: inferring patterns of evolutionary descent
among clusters of related bacterial genotypes from multilocus
sequence typing data. J. Bacteriol. 186, 1518–1530.
[21] Shopsin, B., Gomez, M., Montgomery, S.O., Smith, D.H.,
Waddington, M., Dodge, D.E., Bost, D.A., Riehman, M.,
Naidich, S. and Kreiswirth, B.N. (1999) Evaluation of protein
A gene polymorphic region DNA sequencing for typing of
Staphylococcus aureus strains. J. Clin. Microbiol. 37, 3556–
3563.
[22] Strommenger, B., Cuny, C., Werner, G. and Witte, W. (2004)
Obvious lack of association between dynamics of epidemic
methicillin-resistant Staphylococcus aureus in central Europe and
agr speciﬁcity groups. Eur. J. Clin. Microbiol. Infect. Dis. 23, 15–
19.
[23] Oliveira, D.C. and de Lencastre, H. (2002) Multiplex PCR
strategy for rapid identiﬁcation of structural types and variants of
the mec element in methicillin-resistant Staphylococcus aureus.
Antimicrob. Agents Chemother. 46, 2155–2161.
[24] Ito, T., Kuwahara, K., Hisata, K., Okuma, K., Cui, L. and
Hiramatsu, K. (2004) Community-associated methicillin-resistant
Staphylococcus aureus: current status and molecular epidemio-
logical perspective. J. J. A. Inf. D. 78, 459–469, (in Japanese).
[25] Jarraud, S., Mougel, C., Thioulouse, J., Lina, G., Meugnier, H.,
Forey, F., Nesme, X., Etienne, J. and Vandenesch, F. (2002)
Relationships between Staphylococcus aureus genetic background,
virulence factors, agr groups (alleles), and human disease. Infect.
Immun. 70, 631–641.
[26] Becker, K., Roth, R. and Peters, G. (1998) Rapid and speciﬁc
detection of toxigenic Staphylococcus aureus: use of two multiplex
PCR enzyme immunoassays for ampliﬁcation and hybridization
of staphylococcal enterotoxin genes, exfoliative toxin genes, and
toxic shock syndrome toxin 1 gene. J. Clin. Microbiol. 36, 2548–
2553.
[27] Holtfreter, S., Bauer, K., Thomas, D., Feig, C., Lorenz, V.,
Roschack, K., Friebe, E., Selleng, K., Lovenich, S., Greve, T.,
Greinacher, A., Panzig, B., Engelmann, S., Lina, G. and Broker,
B.M. (2004) egc-Encoded superantigens from Staphylococcus
aureus are neutralized by human sera much less eﬃciently than
are classical staphylococcal enterotoxins or toxic shock syndrome
toxin. Infect. Immun. 72, 4061–4071.
[28] Jarraud, S., Cozon, G., Vandenesch, F., Bes, M., Etienne, J. and
Lina, G. (1999) Involvement of enterotoxins G and I in
staphylococcal toxic shock syndrome and staphylococcal scarlet
fever. J. Clin. Microbiol. 37, 2446–2449.[29] Orwin, P.M., Leung, D.Y., Donahue, H.L., Novick, R.P. and
Schlievert, P.M. (2001) Biochemical and biological properties of
staphylococcal enterotoxin K. Infect. Immun. 69, 360–366.
[30] Zhang, S., Iandolo, J.J. and Stewart, G.C. (1998) The enterotoxin
D plasmid of Staphylococcus aureus encodes a second enterotoxin
determinant (sej). FEMS Microbiol. Lett. 168, 227–233.
[31] Letertre, C., Perelle, S., Dilasser, F. and Fach, P. (2003)
Identiﬁcation of a new putative enterotoxin SEU encoded by
the egc cluster of Staphylococcus aureus. J. Appl. Microbiol. 95,
38–43.
[32] Yamaguchi, T., Nishifuji, K., Sasaki, M., Fudaba, Y., Aepfelb-
acher, M., Takata, T., Ohara, M., Komatsuzawa, H., Amagai, M.
and Sugai, M. (2002) Identiﬁcation of the Staphylococcus aureus
etd pathogenicity island which encodes a novel exfoliative toxin,
ETD, and EDIN-B. Infect. Immun. 70, 5835–5845.
[33] Williams, R.J., Ward, J.M., Henderson, B., Poole, S., O’Hara,
B.P., Wilson, M. and Nair, S.P. (2000) Identiﬁcation of a novel
gene cluster encoding staphylococcal exotoxin-like proteins:
characterization of the prototypic gene and its protein product,
SET1. Infect. Immun. 68, 4407–4415.
[34] Tristan, A., Ying, L., Bes, M., Etienne, J., Vandenesch, F. and
Lina, G. (2003) Use of multiplex PCR to identify Staphylococcus
aureus adhesins involved in human hematogenous infections. J.
Clin. Microbiol. 41, 4465–4467.
[35] Vasudevan, P., Nair, M.K., Annamalai, T. and Venkitanaraya-
nan, K.S. (2003) Phenotypic and genotypic characterization of
bovine mastitis isolates of Staphylococcus aureus for bioﬁlm
formation. Vet. Microbiol. 92, 179–185.
[36] Vancraeynest, D., Hermans, K. and Haesebrouck, F. (2004)
Genotypic and phenotypic screening of high and low virulence
Staphylococcus aureus isolates from rabbits for bioﬁlm formation
and MSCRAMMs. Vet. Microbiol. 103, 241–247.
[37] Martineau, F., Picard, F.J., Lansac, N., Me´nard, C., Roy, P.H.,
Ouellette, M. and Bergeron, M.G. (2000) Correlation between the
resistance genotype determined by multiplex PCR assays and the
antibiotic susceptibility patterns of Staphylococcus aureus and
Staphylococcus epidermidis. Antimicrob. Agents Chemother. 44,
231–238.
[38] Massidda, O., Mingoia, M., Fadda, D., Whalen, M.B.,
Montanari, M.P. and Varaldo, P.E. (2006) Analysis of the
b-lactamase plasmid of borderline methicillin-susceptible
Staphylococcus aureus. Focus on bla complex genes and
cadmium resistance determinants cadD and cadX. Plasmid 55,
114–127.
[39] Choi, S.M., Kim, S.H., Kim, H.J., Lee, D.G., Choi, J.H., Yoo,
J.H., Kang, J.H., Shin, W.S. and Kang, M.W. (2003) Multiplex
PCR for the detection of genes encoding aminoglycoside modi-
fying enzymes and methicillin resistance among Staphylococcus
species. J. Korean Med. Sci. 18, 631–636.
[40] Clark, N.C., Olsvik, O., Swenson, J.M., Spiegel, C.A. and
Tenover, F.C. (1999) Detection of a streptomycin/spectinomycin
adenylyltransferase gene (aadA) in Enterococcus faecalis. Anti-
microb. Agents Chemother. 43, 157–160.
[41] Trzcinski, K., Cooper, B.S., Hryniewicz, W. and Dowson, C.G.
(2000) Expression of resistance to tetracyclines in strains of
methicillin-resistant Staphylococcus aureus. J. Antimicrob. Che-
mother. 45, 763–770.
[42] Aminov, R.I., Garrigues-Jeanjean, N. and Mackie, R.I. (2001)
Molecular ecology of tetracycline resistance: development and
validation of primers for detection of tetracycline resistance genes
encoding ribosomal protection proteins. Appl. Environ. Micro-
biol. 67, 22–32.
[43] Strommenger, B., Kettlitz, C., Werner, G. and Witte, W. (2003)
Multiplex PCR assay for simultaneous detection of nine clinically
relevant antibiotic resistance genes in Staphylococcus aureus. J.
Clin. Microbiol. 41, 4089–4094.
[44] National Committee for Clinical Laboratory Standards. (2003)
Methods for dilution antimicrobial susceptibility tests for bacteria
that grow aerobically, 6th ed. Approved standard M7-A6.
National Committee for Clinical Laboratory Standards, Wayne,
PA.
[45] Clinical and Laboratory Standards Institute. (2005) Performance
standard for antimicrobial susceptibility testing; 15th informa-
tional supplement. M100-S15. Clinical and Laboratory Standards
Institute, Wayne, PA.
2334 I. Taneike et al. / FEBS Letters 580 (2006) 2323–2334[46] Goering, R.V. and Winters, M.A. (1992) Rapid method for
epidemiological evaluation of gram-positive cocci by ﬁeld inver-
sion gel electrophoresis. J. Clin. Microbiol. 30, 577–580.
[47] Nei, M. and Li, W.H. (1979) Mathematical model for studying
genetic variation in terms of restriction endonucleases. Proc. Natl.
Acad. Sci. USA. 76, 5269–5273.
[48] Sabersheikh, S. and Saunders, N.A. (2004) Quantiﬁcation of
virulence-associated gene transcripts in epidemic methicillin
resistant Staphylococcus aureus by real-time PCR. Mol. Cell
Probes. 18, 23–31.
[49] Nakagawa, S., Taneike, I., Mimura, D., Iwakura, N., Nakay-
ama, T., Emura, T., Kitatsuji, M., Fujimoto, A. and Yamam-
oto, T. (2005) Gene sequences and speciﬁc detection for
Panton-Valentine leukocidin. Biochem. Biophys. Res. Commun.
328, 995–1002.
[50] Takahashi, N., Nishida, H., Kato, H., Imanishi, K., Sakata, Y.
and Uchiyama, T. (1998) Exanthematous disease induced by toxic
shock syndrome toxin 1 in the early neonatal period. Lancet 351,
1614–1619.
[51] Takizawa, Y., Taneike, I., Nakagawa, S., Ishii, S., Kurobayashi,
T., Tanaka, K., Gejyo, F. and Yamamoto, T. (2003) Molecular
DNA analysis of methicillin-resistant Staphylococcus aureus
(MRSA) infection in a Neonatal Intensive Care Unit. Acta
Med. Biol. 51, 103–109.
[52] Todd, J.K. (1988) Toxic shock syndrome. Clin. Microbiol. Rev. 1,
432–446.
[53] McDevitt, D., Francois, P., Vaudaux, P. and Foster, T.J. (1994)
Molecular characterization of the clumping factor (ﬁbrinogen
receptor) of Staphylococcus aureus. Mol. Microbiol. 11, 237–248.
[54] Konishi, T. (1994) MRSA enteritis. Nippon Rinsho 6, 45–48, (in
Japanese).[55] Shimada, K. (1986) Methicillin-resistant Staphylococcus aureus.
Nippon Rinsho 44, 2112–2121, (in Japanese).
[56] Fukayama, M. and Inamatsu, T. (1988) Current situation of
methicillin-resistant Staphylococcus aureus infections in elderly
patients. Cin. Microbiol. 15, 174–177, (in Japanese).
[57] Katoh, K., Miyakawa, K., Ohi, H. and Ishiguro, K. (1987)
Current study of methicillin-resistant Staphylococcus aureus
infections in childhood – Report of cases and a review of the
literature. Jpn. J. Ped. 40, 589–594, (in Japanese).
[58] Takesue, Y., Yokoyama, T., Kodama, T., Santou, T., Nakamitsu,
A., Murakami, Y., Imamura, Y., Miyamoto, K., Okita, M.,
Tsumura, H., Hirata, T. and Matsuura, Y. (1993) A study on
postoperative enteritis caused by methicillin-resistant Staphylo-
coccus aureus. Surg. Today 23, 4–8.
[59] Ryde´n, C., Tung, H.S., Nikolaev, V., Engstro¨m, A. and Oldberg,
A. (1997) Staphylococcus aureus causing osteomyelitis binds to a
nonapeptide sequence in bone sialoprotein. Biochem. J. 327, 825–
829.
[60] Tung, H.S., Guss, B., Hellman, U., Persson, L., Rubin, K. and
Ryde´n, C. (2000) A bone sialoprotein-binding protein from
Staphylococcus aureus: a member of the staphylococcal Sdr
family. Biochem. J. 345, 611–619.
[61] Gravet, A., Rondeau, M., Harf-Monteil, C., Grunenberger, F.,
Monteil, H., Scheftel, J.M. and Prevost, G. (1999) Predominant
Staphylococcus aureus isolated from antibiotic-associated diarrhea
is clinically relevant and produces enterotoxin A and the bicom-
ponent toxin LukE–LukD. J. Clin. Microbiol. 37, 4012–4019.
[62] Ferry, T., Thomas, D., Genestier, A.L., Bes, M., Lina, G.,
Vandenesch, F. and Etienne, J. (2005) Comparative prevalence of
superantigen genes in Staphylococcus aureus isolates causing sepsis
with and without septic shock. Clin. Infect. Dis. 41, 771–777.
